These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31010837)

  • 1. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.
    Chen WS; Alshalalfa M; Zhao SG; Liu Y; Mahal BA; Quigley DA; Wei T; Davicioni E; Rebbeck TR; Kantoff PW; Maher CA; Knudsen KE; Small EJ; Nguyen PL; Feng FY
    Clin Cancer Res; 2019 Jul; 25(14):4290-4299. PubMed ID: 31010837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.
    Alshalalfa M; Nguyen PL; Beltran H; Chen WS; Davicioni E; Zhao SG; Rebbeck TR; Schaeffer EM; Lotan TL; Feng FY; Mahal BA
    Eur Urol Oncol; 2019 Jul; 2(4):405-412. PubMed ID: 31164324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of
    Chakraborty G; Armenia J; Mazzu YZ; Nandakumar S; Stopsack KH; Atiq MO; Komura K; Jehane L; Hirani R; Chadalavada K; Yoshikawa Y; Khan NA; Chen Y; Abida W; Mucci LA; Lee GM; Nanjangud GJ; Kantoff PW
    Clin Cancer Res; 2020 Apr; 26(8):2047-2064. PubMed ID: 31796516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
    You GR; Cheng AJ; Lee LY; Huang YC; Liu H; Chen YJ; Chang JT
    BMC Cancer; 2019 Jan; 19(1):64. PubMed ID: 30642292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
    Malorni L; Piazza S; Ciani Y; Guarducci C; Bonechi M; Biagioni C; Hart CD; Verardo R; Di Leo A; Migliaccio I
    Oncotarget; 2016 Sep; 7(42):68012-68022. PubMed ID: 27634906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
    Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
    Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
    von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
    J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence.
    Wu Z; Uhl B; Gires O; Reichel CA
    J Biomed Sci; 2023 Mar; 30(1):21. PubMed ID: 36978029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a survival-related signature for sarcoma patients through integrated transcriptomic and proteomic profiling analyses.
    Zhang B; Yang L; Wang X; Fu D
    Gene; 2021 Jan; 764():145105. PubMed ID: 32882333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA pan-cancer analysis.
    Shao F; Yang X; Wang W; Wang J; Guo W; Feng X; Shi S; Xue Q; Gao S; Gao Y; Lu Z; He J
    Cancer Commun (Lond); 2019 Oct; 39(1):54. PubMed ID: 31578148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel clinical multidimensional transcriptome signature predicts prognosis in bladder cancer.
    Liu CP; Zhang JH; Zheng SC; Liu J; Guo JC
    Oncol Rep; 2018 Nov; 40(5):2826-2835. PubMed ID: 30226624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
    Danaher P; Warren S; Lu R; Samayoa J; Sullivan A; Pekker I; Wallden B; Marincola FM; Cesano A
    J Immunother Cancer; 2018 Jun; 6(1):63. PubMed ID: 29929551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and validation of a novel autophagy-related gene signature for patients with breast cancer.
    Du JX; Chen C; Luo YH; Cai JL; Cai CZ; Xu J; Ni XJ; Zhu W
    Gene; 2020 Dec; 762():144974. PubMed ID: 32707305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression signature of cancer-associated KRAB-ZNF factors identified in TCGA pan-cancer transcriptomic data.
    Machnik M; Cylwa R; Kiełczewski K; Biecek P; Liloglou T; Mackiewicz A; Oleksiewicz U
    Mol Oncol; 2019 Apr; 13(4):701-724. PubMed ID: 30444046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.